

CITATION REPORT

List of articles citing

Lower fracture rates in patients treated with Radium-223, abiraterone or enzalutamide, when given concurrently with bone health agents: A real world analysis

DOI: 10.1016/j.clgc.2022.04.015

Clinical Genitourinary Cancer, 2022, , .

Source: <https://exaly.com/paper-pdf/145167391/citation-report.pdf>

Version: 2024-04-05

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. 9,		0
1	Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. 2023 , 24, 2189		0